ArticleInternational journal of general medicine2025
The Significance of RUNX3 Expression Levels in the Prognosis of Severe Acute Pancreatitis.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the expression levels of RUNX3 in patients with severe acute pancreatitis (SAP) and its impact on disease progression. Methods: Healthy individuals undergoing physical examinations during the same period were selected as a control group. General patient data were analyzed and compared. Enzyme-linked immunosorbent assay (ELISA) was used to detect the expression levels of RUNX3, and differences in RUNX3 levels between the groups were compared. Results: Comparison of general characteristics showed no statistically significant differences in sex, age, body mass index (BMI), history of diabetes, hypertension, coronary artery disease, etiology, or prevalence of fatty liver among the groups (P > 0.05). The time from onset to admission and the length of hospital stay were significantly higher in the severe group compared to the mild group (P = 0.001). The severe group also exhibited significantly higher white blood cell counts (WBC), procalcitonin (PCT), C-reactive protein (CRP), lipase (LPS), and APACHE II scores (P = 0.001). RUNX3 levels were 97.67 ± 31.03 in the SAP group, significantly lower than 137.22 ± 53.07 in the mild group and 217.55 ± 76.59 in the control group (P < 0.05). Pearson correlation analysis revealed a negative correlation between RUNX3 levels and APACHE II scores in patients with acute pancreatitis (r = -0.613, P < 0.0152). RUNX3 levels in the poor prognosis group were significantly lower than those in the good prognosis group (P < 0.05). ROC curve analysis indicated that the area under the curve for RUNX3 levels in predicting the prognosis of acute pancreatitis was 0.835, with an optimal cutoff value of 162.31 pg/mL, a sensitivity of 90.00%. Conclusion: RUNX3 expression levels are significantly reduced in patients with SAP and are negatively correlated with disease severity, making them a potential biomarker for assessing and predicting the prognosis of acute pancreatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.